Heather M. Colvin is a Project Director within the Biomedical Innovation and Evidence Development team at the Duke-Margolis Center for Health Policy. In this role, she manages a broad portfolio of projects that seek to advance the innovation, regulation and long-term evaluation of drugs, biologics and medical devices. Her current activities focus on policies that expand the ability to evaluate marketed medical products, as well as strategies to incorporate the patient voice into regulatory decision-making.
Prior to joining Duke-Margolis, Heather was a Project Director at the Brookings Institution where she managed cooperative agreements with FDA that including projects such as the Planning Board for the National Evaluation System for health Technology (NEST), Brookings Council on Antibacterial Drug Development, and ongoing support of FDA’s Sentinel Initiative.
She was program officer at the National Academy of Sciences’ Institute of Medicine for several years. In that role, she worked several consensus studies including the evaluation of the regulatory pathway for moderate risk medical devices, and prevention and control programs for viral hepatitis B and C. She has also served as an International Health Officer for the Department of Health and Human Services’ Office of Global Health, and a policy analyst on managed care performance measurement for both the National Committee for Quality Assurance and Towers Perrin (now Towers Watson).
Master of Public Policy, Georgetown University
Bachelor of Arts, Cultural Anthropology, George Mason University.